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Diuretic resistance in heart failure is defined as a state in which diuretic response is diminished or lost
before the therapeutic goal of relief from congestion has been reached. Diuretic resistance is very common
and is associated with poor outcomes. Over the past decade, several new drugs and devices targeting
decongestion and improvement in renal function in patients with heart failure have failed to show benefit
in randomized clinical trials. Glucocorticoids had been used to manage diuretic resistance before the
advent of loop diuretics. More recent evidence appears to confirm that glucocorticoids may also help
to overcome resistance to loop diuretics. This review tries to summarize the available evidence and poten-
tial mechanisms related to glucocorticoid therapy in patients with heart failure and its effect on diuretic
resistance. (J Cardiac Fail 2014;20:625e629)Key Words: Heart failure, diuretic resistance, glucocorticoids.Chronic heart failure (HF) is a leading cause of cardiovas-
cular morbidity and mortality in the world and is an emerging
epidemic of the 21st century. Diuretics remain the corner-
stone of therapy to relieve fluid retention in HF patients.
However, after an initial adequate response to diuretics, pa-
tients with acute decompensated heart failure (ADHF)
develop cardiorenal syndrome and diuretic resistance.
Diuretic resistance is not uncommon, especially in pa-
tients with New York Heart Association functional class
3e4 symptoms, is reported to occur in w30% of patients
with HF on diuretic therapy, and is a challenging clinical
problem.1 The mechanisms of diuretic resistance in HF aret Center, First Hospital of Hebei Medical University,
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625complex and include delayed absorption of the diuretic,
reduced secretion of the diuretic into the tubular lumen,
hypertrophy and hyperplasia of epithelial cells of the distal
convoluted tubule, development of renal dysfunction or car-
diorenal syndrome, and blunted renal responsiveness to
natriuretic peptides owing to decreased density of natriuretic
peptide receptors in the kidney.1 Several approaches have
been tried to overcome diuretic resistance by targeting the
above mechanisms, including sequential nephron blockade
with different diuretics, increasing diuretic dosage, and vari-
ation of administration route (intravenous). These ap-
proaches used alone or in combination have proved to be
effective in some but not in all cases. Over the past decade,
several new drugs and devices, such as vasopressin receptor
blockers, adenosine A1-receptor antagonist, recombinant hu-
man B-type natriuretic peptide, low-dose dopamine, and ul-
trafiltration, targeting decongestion and improvement in
renal function in patients with ADHF have failed to show
benefit in large-scale randomized clinical trials.2e5 There-
fore, there is urgent need for new drugs that improve renal
responsiveness to diuretic therapy.
Current Perspective of Corticosteroids in HF
In vitro, glucocorticoids have variable affinities for miner-
alocorticoid receptor (MR), ie, mineralocorticoid properties,
626 Journal of Cardiac Failure Vol. 20 No. 9 September 2014owing to their molecular similarity to aldosterone. The 2013
American Heart Association/American College of Cardiol-
ogy Foundation guidelines currently list ‘‘steroids’’ among
common precipitants of ADHF.6 However, an enzyme,
11-beta hydroxysteroid dehydrogenase type II, exists in
mineralocorticoid target tissues that can prevent MR
overstimulation by glucocorticoids and allow selective
mineralocorticoid action by catalyzing the deactivation of
glucocorticoids to 11-dehydro metabolites.7 This is why
cortisol, which circulates at 100e1,000-fold higher concen-
trations than aldosterone,8 and binds with equal affinity to
MR, does not overstimulate MR in normal subjects or
patients with stable HF. Although adverse effects, eg, facial
and leg swelling, weight gain, and hypertension, have been
implicated with the use of glucocorticoids, there are no
data supporting the concern of sodium retention with the
use of glucocorticoids in patients with HF. Weight gain, a
common adverse effect of chronic glucocorticoid use, is
actually induced mostly by increasing food intake through
the central regulation of appetite.9 Rather, there is ever
more emerging evidence from nonhuman and clinical studies
suggesting that glucocorticoids with minimal mineralocorti-
coid properties could potentiate diuretic effect in HF.10Fig. 1. Potential potentiating diuretic mechanisms of glucocorticoids in
glucocorticoid receptor, a ligand-dependent transcription factor. The liga
(NPR-A) gene expression by binding to specific DNA sequences (ie, gl
glucocorticoid-regulated NPR-A gene. The glucocorticoid receptor (G
NPR-A gene expression in the hypothalamus and kidney.Newly Emerging Potential Mechanisms of
Glucocorticoids in HF
The mechanisms of diminished renal responsiveness to
diuretics are complex. Several mechanisms have been pro-
posed, including blunted renal responsiveness to endoge-
nous natriuretic peptides due to reduced natriuretic
peptide receptor A (NPR-A) in the kidney, renal vasocon-
striction, and inflammation activation.11
Glucocorticoids have been shown to play a key role in
body fluid control through mediating the gene expression
of NPR-A by binding to specific DNA sequences, ie, gluco-
corticoid response element (Fig. 1).12,13 We found that glu-
cocorticoids could act on the hypothalamus as well as the
kidney to assist in the normalization of extracellular fluid
volume through up-regulating NPR-A density in the hypo-
thalamus and kidney.12,13 In the kidney, glucocorticoids
improved renal responsiveness to atrial natriuretic peptide
(ANP) by increasing NPR-A density in the renal inner med-
ullary collecting duct.12 In the hypothalamus, glucocorti-
coids inhibited dehydration-induced water intake by
potentiating hypothalamic response to ANP.13 The effects
may work in concert to keep the body fluid volume inheart failure. Glucocorticoids bind to and activate the cytoplasmic
nd-activated receptor dimer activates natriuretic peptide receptor A
ucocorticoid response element [GRE]) in the promoter regions of
R) increases responsiveness to natriuretic peptides by activating
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homeostasis. It is noteworthy that the effect of glucocorti-
coids on NPR-A expression has been observed in both
time- and dose-dependent patterns, ie, the NPR-A expression
in the hypothalamus and kidney increased with increasing
glucocorticoid concentration and time. Moreover, there is ev-
idence demonstrating that glucocorticoids can dilate renal
vasculature, thereby increasing renal plasma flow and
glomerular filtration rate.14 The glucocorticoid-induced renal
vasodilation involves multiple pathways, which include
increased renal prostaglandin, nitric oxide, and dopamine
production.15 Finally, as antiinflammatory agents, glucocorti-
coids may play a disease-modifying role in cardiorenal syn-
drome. In HF, several neurohormones and proinflammatory
cytokines are activated.11 Inflammatory response, in turn,
may further worsen renin-angiotensin-aldosterone and sym-
pathetic nervous system activation and cause renal injury.
Therefore, the antiinflammatory role of glucocorticoids in
attenuating diuretic resistance in HF can not be excluded
and merits further investigations.
Historical Review of Adrenocorticotropic Hormone
(ACTH)/Glucocorticoid Use in HF
Use of Steroids in PreeLoop Diuretic Era
In the 1950s, physicians used ACTH/glucocorticoids in pa-
tients with refractory HF based on the assumption that these
patients suffer adrenal or pituitary insufficiency. Several case
reports supporting the use of glucocorticoids to improve renal
responsiveness to diuretic therapy in HF have been published
(Supplemental Table 1). In 3 large prospective clinical series,
ACTH/glucocorticoids successfully reversed mercurial
diuretic resistance in most of the cases.16e18
Use of Steroids in Loop Diuretic Era
With the introduction of loop diuretics into clinical prac-
tice, physicians discontinued the use of steroids. However,
as the population of patients with end-stage HF increased
dramatically, diuretic resistance became more common.
Recent data show that glucocorticoids can successfully over-
come diuretic resistance in this population who fail to
respond to loop or combined diuretic therapy.15,19,20Fig. 2. The effect of prednisone on daily urine output and renal electroly
were treated with prednisone or placebo for 7 days; n 5 10 in each grou
Liu et al.21Ashbel et al assessed the effects of prednisone and meth-
ylprednisolone in HF patients with blunted response to
furosemide (80 mg/d).19 Compared with baseline, predni-
sone doubled and methylprednisolone tripled daily urine
output after a 3-day treatment. As a result, both prednisone
and methylprednisolone reverted renal responsiveness to
furosemide, leading to a dramatic body weight reduction.
We evaluated the effect of prednisone (1 mg kg1 d1
with a maximum dose of 60 mg/d) in 13 patients with
ADHF and diuretic resistance, defined as the failure to
attain a negative fluid balance despite use of furosemide
(O200 mg/d), hydrochlorothiazide (O50 mg/d), spirono-
lactone (O50e100 mg/d), and positive inotropic agents.
All drugs were administered for $3 days before diuretic
resistance was diagnosed.20 Prednisone successfully
reversed diuretic resistance in all patients and produced a
potent diuresis with significant body weight loss
(9.4 6 3.1 kg) over 4 weeks as well as significantly
decreased serum creatinine (sCr) from 1.52 6
0.70 mg/dL at baseline to 0.90 6 0.33 (P ! .01).Controlled Clinical Trials of Glucocorticoid
Use in HF
To determine whether glucocorticoids cause sodium and
water retention in patients with HF, 20 clinically stable HF
patients without overt fluid retention, who were receiving
standard drug therapy, were randomized to receive predni-
sone (1 mg kg1 d1 with a maximum dose of 60 mg/d) or
placebo for 7 days.21 During this period, prednisone caused
striking diuresis and natriuresis (Fig. 2). Of note, there was
a 3-day latent period for prednisone to take effect. This
study challenged the widespread notion that glucocorticoids
cause renal sodium and water retention in patients with HF.
In patients with HF, diuretic use is often associated with
the development of hyperuricemia.22 We found that predni-
sone could dramatically increase the renal responsiveness to
diuretic therapy, lower serum uric acid concentration, and
improve renal function in HF patients with hyperuricemia.23
To test whether glucocorticoids could prevent the devel-
opment of renal dysfunction, which is often seen withte excretion in clinically stable heart failure patients. The patients
p. *Significant difference compared with placebo (P! .05). From
628 Journal of Cardiac Failure Vol. 20 No. 9 September 2014diuretic therapy, 102 patients with ADHF were randomized
to receive glucocorticoids (1 20-mg dose of dexamethasone
followed by 1 mg kg1 d1 prednisone with a maximum
dose of 60 mg/d for 7 days) plus diuretics or standard
diuretic therapy alone.24 The change in sCr from baseline
was 0.14 mg/dL in the glucocorticoid group versus
0.02 mg/dL in the standard-treatment group (P ! .05).
Cardiovascular death within 30 days occurred in 3 patients
in the glucocorticoid group compared with 10 patients in
the standard-care group (P! .05). These patients were fol-
lowed for a median of 19 months (range 1e36 months).
The survival benefit in the glucocorticoid group persisted
during the follow-up period (P 5 .037). Several key limita-
tions of this study compromised its interpretation. First, the
study was not powered to determine a difference in mortal-
ity between groups. Second, the study was not blinded and
allowed care providers to select and adjust diuretic doses
(mean doses between groups were not recorded). Therefore,
considerable bias in the use of diuretics can exist, affecting
the efficacy of glucocorticoid therapy.
In 1986, Stubbs et al studied the efficacy and safety
profile of methylprednisolone on mortality in patients with
acute myocardial infraction complicated by ADHF. They
conducted 2 trials in different populations.25 The 1st trial
was in patients whose medical intervention was initiated
within 6 hours of the onset of chest pain (early intervention
group), and the 2nd was in patients whose medical interven-
tion was initiatedO6 hours from the onset of chest pain (late
intervention group). Patents in both trials were randomized
to receive methylprednisolone (30 mg/kg intravenously,
repeated 3 hours later) or placebo. Methylprednisolone
improved HF outcomes. The pooled data showed that meth-
ylprednisolone reduced mortality caused by pump failure
(relative risk 0.51, 95% CI 0.28e0.94; P 5 .03). A hemody-
namic and metabolic study was performed in a small subset
of patients from the study. That study revealed that glucocor-
ticoids caused an increase in cardiac output and diuresis, but
a decrease in blood volume.26
In 2010, Mady and Guindy reported their results on the use
of glucocorticoids to treat patients with ADHF refractory to
standard medical treatment.27 Forty patients received either
prednisone (1 mg kg1 d1 with maximum dosage of
60 mg/d) or standard treatment. Adding prednisone to
standard treatment doubled daily urine output (P ! .001).
As a result, HF symptoms were markedly improved in 80%
of the patients at the end of the study (P! .001). The level
of sCr was reduced from 1.6 mg/dL at baseline to 0.9 mg/
dL at the end of the study (P! .01) in the patients given pred-
nisone, whereas sCr increased from 1.2 mg/dL at baseline to
1.3 mg/dL in patients receiving standard treatment.
Adverse Effects and Limitations of
Glucocorticoids in Heart Failure
Glucocorticoids have multiple adverse effects, especially
when used in large doses and over the long term. These side
effects include disturbances in glucose tolerance,susceptibility to infection, sleep disorder, hyperactivity,
osteoporosis, and muscle wasting. In addition, all clinical
evidence of glucocorticoid in HF is based on short-term
use. Therefore, long-term glucocorticoid use should be
avoided in patients with HF. Additionally, glucocorticoids
were administrated as an add-on therapy in all clinical
studies, and there is no evidence that they can improve
renal function in the absence of diuretic therapy in HF.Perspective
In light of the evidence provided, the short-term use of
glucocorticoids with minimal mineralocorticoid action in
patients with HF, when indicated for the treatment of other
acute comorbid conditions, eg, acute gout, is safe and
perhaps even advantageous. The short-term use of gluco-
corticoids, when added to maximum conventional therapy,
can potentiate renal responsiveness to diuretic therapy in
patients with HF. However, a larger properly powered ran-
domized double-blind placebo-controlled study is war-
ranted to demonstrate their safety and efficacy in such
patients. The underlying mechanisms of using glucocorti-
coids to increase renal responsiveness to the diuretics are
complex and also need to be clarified further.Acknowledgments
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